Octant snags $80m Series B
Octant, Inc, a developer of programmable biology and chemistry to build precision medicines for complex diseases, has raised $80 million in Series B financing.
Octant, Inc, a developer of programmable biology and chemistry to build precision medicines for complex diseases, has raised $80 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination